CP
XENE icon

Caligan Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Caligan Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-549,700
Closed -$24.6M – 34
2025
Q4 		$24.6M Buy
+549,700
New +$23.1M 2.03% 12

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Caligan Partners's XENE Position: Q2 2026 in Review

Caligan Partners reduced its Xenon Pharmaceuticals (XENE) stake by 36% in Q2 2026, selling an estimated $27.9M and leaving 889,944 shares worth $53.7M. The position accounts for 2.53% of the portfolio, ranked #8.

Caligan Partners first reported a position in XENE in Q3 2025 and has held it in 4 quarters since. The position peaked at $81M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Caligan Partners held 889,944 shares of Xenon Pharmaceuticals worth $53.7M as of Q2 2026.
  • Caligan Partners sold 503,083 Xenon Pharmaceuticals shares in Q2 2026, an estimated $27.9M.
  • Xenon Pharmaceuticals made up 2.53% of Caligan Partners's portfolio in Q2 2026, its #8 holding.
  • Caligan Partners first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Caligan Partners's Xenon Pharmaceuticals position peaked at $81M in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.